VEGF and mTOR inhibitors 

VEGF tyrosine kinase inhibitors

(e.g., sunitinib, sorafenib, ponatinib, pazopanib, cabozantinib, lenvatinib, nintedanib,vandetanib, axitinib, regorafenib)

VEGF monoclonal antibodies

(e.g., bevacizumab, aflibercept, ramucirumab)

mTOR inhibitors

(e.g., everolimus, temsirolimus)

Cardio-oncological evaluation*

before cancer treatment begins

Cardio-oncological evaluation* AND home blood pressure monitoring

every 3 months for 1 year, then every 6 months during cancer treatment

* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.